A post hoc analysis of a Lennox-Gastaut trial reported fewer seizure-related injuries among clobazam recipients than placebo recipients.
A clinically tangible endpoint
Medical review classified injury events from adverse-event listings in the phase-three trial. Seizure-related injuries occurred in 8.9% across clobazam groups versus 27.1% with placebo. Most classified events were mild or moderate; the reported serious jaw fracture occurred in the placebo group.
Post hoc ascertainment limits the estimate
Injury was examined retrospectively rather than as the trial’s primary prospectively specified outcome. Classification depended on available event descriptions, and group-level findings do not guarantee protection for every patient. The analysis also does not mean clobazam cannot contribute to other kinds of falls or sedation. Its value is showing a possible downstream benefit of seizure reduction, while retaining the distinction between seizure-related injury, all injury, and medication adverse effects. Trial reanalysis should be described explicitly rather than presented as a new injury-prevention trial.
Source paper
Original analysis of the supplied journal article, identified as PMC5021111.
Leave a Reply